How GLP-1 Medications Work

Glucagon-like peptide-1 receptor agonists, medications commonly known by their brand names Ozempic, Wegovy, Victoza, Trulicity, and Mounjaro (the latter acting on both GLP-1 and GIP receptors), have rapidly transformed the clinical landscape for type 2 diabetes and obesity treatment. The scale of weight loss achieved in landmark clinical trials exceeded anything previously seen with non-surgical interventions, and cardiovascular outcome data has added a further dimension to their clinical value.

Understanding how these medications work, what GLP-1 is, how the receptor agonists mimic and amplify its effects, and what biological pathways produce the observed outcomes, is important both for clinical professionals guiding patients and for individuals considering or using these treatments.

What GLP-1 Is and What It Does Naturally

GLP-1 (glucagon-like peptide-1) is a hormone produced by L-cells in the gut lining, primarily in the ileum and colon. It is released in response to nutrient ingestion, particularly fat and carbohydrates and has a very short half-life in circulation (1-2 minutes) because it is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4). This rapid degradation limits its physiological impact and makes the native hormone unsuitable as a therapeutic agent.

Endogenous GLP-1 exerts its effects through GLP-1 receptors expressed in the pancreas, gut, heart, kidney, and brain. In the pancreas, it stimulates insulin secretion from beta cells in a glucose-dependent manner (meaning it only stimulates insulin when glucose is elevated, which importantly limits hypoglycemia risk) and suppresses glucagon release from alpha cells. In the gut, it slows gastric emptying. In the brain, it acts on hypothalamic and brainstem GLP-1 receptors to reduce appetite and food intake.

GLP-1 Receptor Agonists as Medications

GLP-1 receptor agonists are synthetic molecules designed to bind to the GLP-1 receptor and activate it, mimicking the effects of endogenous GLP-1 but with dramatically longer half-lives that allow once-daily or once-weekly administration. They are not identical to native GLP-1, they are engineered variants with resistance to DPP-4 degradation.

Semaglutide (marketed as Ozempic for type 2 diabetes at lower doses and as Wegovy for obesity at higher doses) has a half-life of approximately one week, allowing once-weekly injection. Liraglutide (Victoza/Saxenda) requires once-daily injection. Tirzepatide (Mounjaro/Zepbound) is a dual agonist acting on both GLP-1 and GIP receptors, showing even greater weight loss efficacy than GLP-1 agonism alone in clinical trials. Oral semaglutide formulations (Rybelsus) exist for type 2 diabetes treatment, though with lower bioavailability than the injectable forms.

How They Cause Weight Loss

The weight loss produced by GLP-1 receptor agonists is primarily mediated through appetite reduction and decreased caloric intake rather than increased energy expenditure. GLP-1 receptors in the hypothalamus (particularly in the arcuate nucleus) and in the brainstem (nucleus tractus solitarius and area postrema) signal satiety and reduce food intake. GLP-1 receptors in the nucleus accumbens and other limbic areas reduce the reward value of food, particularly highly palatable foods.

In the STEP trials with semaglutide 2.4mg weekly, participants achieved an average weight loss of approximately 15% of body weight over 68 weeks, a magnitude previously only achievable with bariatric surgery. Tirzepatide in the SURMOUNT trials achieved average weight losses of 20-22%. These results are achieved primarily through reduced caloric intake; participants typically report reduced appetite, earlier satiety, and decreased interest in food.

Slowed gastric emptying also contributes to reduced post-meal caloric intake, though this effect diminishes somewhat with long-term use. The brain-mediated appetite effects appear to be the dominant mechanism for weight loss in both diabetic and non-diabetic individuals.

Cardiovascular and Other Effects

Beyond weight and glucose management, GLP-1 receptor agonists have demonstrated significant cardiovascular benefits in high-risk populations. The LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) trials all demonstrated meaningful reductions in major adverse cardiovascular events (MACE), heart attack, stroke, and cardiovascular death, in individuals with established cardiovascular disease or high risk. The SELECT trial showed that semaglutide reduced MACE in a non-diabetic obesity population as well.

GLP-1 receptors are expressed in the heart and vascular endothelium, and direct cardioprotetive effects beyond those mediated by weight loss and glucose control have been proposed, including anti-inflammatory and anti-atherosclerotic effects. The medications also reduce blood pressure and triglycerides, and show beneficial signals for non-alcoholic fatty liver disease and kidney protection. The breadth of cardiometabolic benefit has driven significant expansion in clinical indication consideration.

Side Effects and Considerations

The most common side effects are gastrointestinal, nausea, vomiting, diarrhea, and constipation, which occur primarily during dose escalation and tend to diminish over time for most patients. Starting at low doses and titrating gradually over weeks to months is standard practice to improve tolerability. Delayed gastric emptying can cause aspiration risk concerns with anesthesia if the medication is not stopped prior to surgery.

Less common but notable considerations include a theoretical risk of pancreatitis (based on early concerns that have not been confirmed at elevated rates in large trials), a label warning about thyroid C-cell tumors based on rodent carcinogenicity studies (not observed in human trials at current follow-up durations), and potential muscle mass loss that warrants attention, particularly in the absence of adequate protein intake and resistance training.

Who Benefits Most

GLP-1 receptor agonists are currently approved primarily for type 2 diabetes (multiple agents) and for obesity management with BMI ≥30 or BMI ≥27 with weight-related comorbidities (semaglutide, tirzepatide in the U.S.). Within these populations, response varies considerably, some individuals achieve 20%+ weight loss, while others achieve substantially less. The reasons for this variation are an active area of research and likely involve genetic variation in GLP-1 receptor signaling, baseline appetite regulatory function, gut microbiome composition, and other factors.

Individuals with type 2 diabetes or pre-diabetes, elevated cardiovascular risk, and metabolic syndrome components tend to show robust responses. Emerging evidence on genetic predictors of GLP-1 response, including GLP1R variants, may in future allow better prediction of who will respond most favorably, supporting truly personalized prescribing decisions.

Key Takeaways

GLP-1 is a gut-derived hormone that stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite via brain receptors. GLP-1 receptor agonists mimic these effects with long half-lives allowing weekly dosing. Weight loss is primarily achieved through appetite reduction and decreased caloric intake. Average weight loss of 15-22% of body weight in clinical trials exceeds any previous non-surgical intervention. Significant cardiovascular benefits have been demonstrated in multiple large outcome trials. Side effects are primarily gastrointestinal and manageable with gradual titration. Individual response varies considerably, with genetic variation in GLP-1 signaling pathways likely contributing.